The Experts below are selected from a list of 147 Experts worldwide ranked by ideXlab platform
Maria Careri - One of the best experts on this subject based on the ideXlab platform.
-
innovative gold free carbon nanotube chitosan based competitive immunosensor for determination of hiv related P24 Capsid Protein in serum
RSC Advances, 2017Co-Authors: Marco Giannetto, Monica Costantini, Monica Mattarozzi, Maria CareriAbstract:In the past decade, the need for simple, rapid, sensitive, specific and inexpensive screening methods for diagnosis of HIV infection has led to a focus on the HIV1-related Capsid Protein P24. In this work, the first competitive electrochemical immunosensor for the detection of P24 in untreated human serum was developed as a simple, easy-to-use and promising tool for serum screening for early diagnosis of HIV infection. The immunodevice was implemented on disposable gold-free single-walled carbon nanotube-functionalized screen-printed electrodes. The competitive sensor is based on the immobilization of the target Protein on the electrode surface using a chitosan/glutaraldehyde crosslinking system, able to ensure, under mild conditions, a robust immobilization and a proper exposition of P24 for interaction with a mouse anti-P24 IgG1. The immunosensor setup as well as the assay's experimental conditions were then optimized, achieving a wide linear detection range of 10 pM to 1 nM, with a low detection limit of 2 pM in human serum. The good performance, also in terms of selectivity, trueness and precision, coupled with the advantages of an easy preparation compared to other methods requiring very complex conjugation procedures between bioreceptors and expensive nanostructures, makes the immunosensor a powerful diagnostic tool, valuable for implementation of large-scale screening programs for early diagnosis of seropositivity.
-
Innovative gold-free carbon nanotube/chitosan-based competitive immunosensor for determination of HIV-related P24 Capsid Protein in serum
RSC Advances, 2017Co-Authors: Marco Giannetto, Monica Costantini, Monica Mattarozzi, Maria CareriAbstract:In the past decade, the need for simple, rapid, sensitive, specific and inexpensive screening methods for diagnosis of HIV infection has led to a focus on the HIV1-related Capsid Protein P24. In this work, the first competitive electrochemical immunosensor for the detection of P24 in untreated human serum was developed as a simple, easy-to-use and promising tool for serum screening for early diagnosis of HIV infection. The immunodevice was implemented on disposable gold-free single-walled carbon nanotube-functionalized screen-printed electrodes. The competitive sensor is based on the immobilization of the target Protein on the electrode surface using a chitosan/glutaraldehyde crosslinking system, able to ensure, under mild conditions, a robust immobilization and a proper exposition of P24 for interaction with a mouse anti-P24 IgG1. The immunosensor setup as well as the assay's experimental conditions were then optimized, achieving a wide linear detection range of 10 pM to 1 nM, with a low detection limit of 2 pM in human serum. The good performance, also in terms of selectivity, trueness and precision, coupled with the advantages of an easy preparation compared to other methods requiring very complex conjugation procedures between bioreceptors and expensive nanostructures, makes the immunosensor a powerful diagnostic tool, valuable for implementation of large-scale screening programs for early diagnosis of seropositivity.
David H. Wilson - One of the best experts on this subject based on the ideXlab platform.
-
Rapid, Fully Automated Digital Immunoassay for P24 Protein with the Sensitivity of Nucleic Acid Amplification for Detecting Acute HIV Infection
Clinical chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was 4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
-
rapid fully automated digital immunoassay for P24 Protein with the sensitivity of nucleic acid amplification for detecting acute hiv infection
Clinical Chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was <10% for samples as low as 0.09 ng/L. Clinical specificity was 95.1%. Sensitivity concordance vs NAT-VL on dilutions of preseroconversion samples and Group M viral isolates was 100%. Conclusions: The digital immunoassay exhibited >4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
Marco Giannetto - One of the best experts on this subject based on the ideXlab platform.
-
innovative gold free carbon nanotube chitosan based competitive immunosensor for determination of hiv related P24 Capsid Protein in serum
RSC Advances, 2017Co-Authors: Marco Giannetto, Monica Costantini, Monica Mattarozzi, Maria CareriAbstract:In the past decade, the need for simple, rapid, sensitive, specific and inexpensive screening methods for diagnosis of HIV infection has led to a focus on the HIV1-related Capsid Protein P24. In this work, the first competitive electrochemical immunosensor for the detection of P24 in untreated human serum was developed as a simple, easy-to-use and promising tool for serum screening for early diagnosis of HIV infection. The immunodevice was implemented on disposable gold-free single-walled carbon nanotube-functionalized screen-printed electrodes. The competitive sensor is based on the immobilization of the target Protein on the electrode surface using a chitosan/glutaraldehyde crosslinking system, able to ensure, under mild conditions, a robust immobilization and a proper exposition of P24 for interaction with a mouse anti-P24 IgG1. The immunosensor setup as well as the assay's experimental conditions were then optimized, achieving a wide linear detection range of 10 pM to 1 nM, with a low detection limit of 2 pM in human serum. The good performance, also in terms of selectivity, trueness and precision, coupled with the advantages of an easy preparation compared to other methods requiring very complex conjugation procedures between bioreceptors and expensive nanostructures, makes the immunosensor a powerful diagnostic tool, valuable for implementation of large-scale screening programs for early diagnosis of seropositivity.
-
Innovative gold-free carbon nanotube/chitosan-based competitive immunosensor for determination of HIV-related P24 Capsid Protein in serum
RSC Advances, 2017Co-Authors: Marco Giannetto, Monica Costantini, Monica Mattarozzi, Maria CareriAbstract:In the past decade, the need for simple, rapid, sensitive, specific and inexpensive screening methods for diagnosis of HIV infection has led to a focus on the HIV1-related Capsid Protein P24. In this work, the first competitive electrochemical immunosensor for the detection of P24 in untreated human serum was developed as a simple, easy-to-use and promising tool for serum screening for early diagnosis of HIV infection. The immunodevice was implemented on disposable gold-free single-walled carbon nanotube-functionalized screen-printed electrodes. The competitive sensor is based on the immobilization of the target Protein on the electrode surface using a chitosan/glutaraldehyde crosslinking system, able to ensure, under mild conditions, a robust immobilization and a proper exposition of P24 for interaction with a mouse anti-P24 IgG1. The immunosensor setup as well as the assay's experimental conditions were then optimized, achieving a wide linear detection range of 10 pM to 1 nM, with a low detection limit of 2 pM in human serum. The good performance, also in terms of selectivity, trueness and precision, coupled with the advantages of an easy preparation compared to other methods requiring very complex conjugation procedures between bioreceptors and expensive nanostructures, makes the immunosensor a powerful diagnostic tool, valuable for implementation of large-scale screening programs for early diagnosis of seropositivity.
Michael P. Busch - One of the best experts on this subject based on the ideXlab platform.
-
Rapid, Fully Automated Digital Immunoassay for P24 Protein with the Sensitivity of Nucleic Acid Amplification for Detecting Acute HIV Infection
Clinical chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was 4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
-
rapid fully automated digital immunoassay for P24 Protein with the sensitivity of nucleic acid amplification for detecting acute hiv infection
Clinical Chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was <10% for samples as low as 0.09 ng/L. Clinical specificity was 95.1%. Sensitivity concordance vs NAT-VL on dilutions of preseroconversion samples and Group M viral isolates was 100%. Conclusions: The digital immunoassay exhibited >4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
Carlos Cabrera - One of the best experts on this subject based on the ideXlab platform.
-
Rapid, Fully Automated Digital Immunoassay for P24 Protein with the Sensitivity of Nucleic Acid Amplification for Detecting Acute HIV Infection
Clinical chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was 4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
-
rapid fully automated digital immunoassay for P24 Protein with the sensitivity of nucleic acid amplification for detecting acute hiv infection
Clinical Chemistry, 2015Co-Authors: Carlos Cabrera, Lei Chang, Mars Stone, Michael P. Busch, David H. WilsonAbstract:Background: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital P24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. Methods: We developed an investigational 69-min immunoassay for P24 Capsid Protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of P24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary P24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. Results: Analytical sensitivity was 0.0025 ng/L P24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was <10% for samples as low as 0.09 ng/L. Clinical specificity was 95.1%. Sensitivity concordance vs NAT-VL on dilutions of preseroconversion samples and Group M viral isolates was 100%. Conclusions: The digital immunoassay exhibited >4000-fold greater sensitivity than contemporary immunoassays for P24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
